Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02321501 · ClinicalTrials.gov registry record · Phase 1

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

A Phase 1 study of Metastatic Malignant Solid Neoplasm and Locally Advanced Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
37
Enrollment target
1
Study location

NCT02321501 is a Phase 1 study of Metastatic Malignant Solid Neoplasm and Locally Advanced Malignant Solid Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02321501, a Phase 1 study of Metastatic Malignant Solid Neoplasm and Locally Advanced Malignant Solid Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic) or stage IIIB-IV non-small cell lung cancer. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Metastatic Malignant Solid Neoplasm Locally Advanced Malignant Solid Neoplasm Stage IV Lung Non-Small Cell Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 ALK Positive ROS1 Gene Rearrangement

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Everolimus
  • DRUG Ceritinib
  • OTHER Pharmacological Study

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2016-06-22
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02321501

The ClinicalTrials.gov registry entry for NCT02321501 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 92 other Metastatic Malignant Solid Neoplasm trials with a reported enrollment target (82% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Metastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02321501 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02321501 about?

NCT02321501 is a clinical study titled "Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer". This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic) or stage IIIB-IV non-small cell lung ca...

What is the current status of trial NCT02321501?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2016-06-22. Estimated completion is 2026-12-31.

What conditions does trial NCT02321501 study?

This clinical trial studies the following conditions: Metastatic Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, ALK Positive.

What interventions are being tested in trial NCT02321501?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Everolimus (DRUG), Ceritinib (DRUG), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT02321501?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02321501 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Malignant Solid Neoplasm

All registered trials for this condition

Locally Advanced Malignant Solid Neoplasm

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.